• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Disclosed are uses of Danshen or Danshen preparation in preparation of drugs for treating diseases related to hepatic fibrosis.
    公开号:AU2013207295A1
    申请号:U2013207295
    申请日:2013-01-04
    公开日:2014-07-24
    发明作者:Jinfang HU；Jie Ma；Xiuping SHEN；Yonghong Zhu
    申请人:Tasly Pharmaceutical Group Co Ltd；
    IPC主号:A61K36-537
    专利说明:
    USE OF RADIX SALVIA MILTIORRHIZAE (DANSHEN) OR ITS PREPARATIONS IN PREPARATION OF DRUGS FOR TREATING DISEASES RELATED TO HEPATIC FIBROSIS 5 FIELD OF THE INVENTION The present invention relates to the field of medicine, in particular to a use of Radix Salviae Miltiorrhizae or its preparations in treating diseases related to hepatic fibrosis. BACKGROUD OF THE INVENTION 10 Hepatic fibrosis is regarded to be an inevitable stage in liver cirrhosis and therefore anti hepatic fibrosis becomes a very important treating method. Now, the effective anti hepatic fibrosis medicine is still deficient in clinic. Although several drugs including the cytokines and antioxidant had been studied under clinical research, their clinical efficacy was unsatisfactory. Recently, the traditional Chinese medicine 15 (TCM) has increasingly gained prominence in anti-hepatic fibrosis, showing a promising application prospect. Radix Salviae Miltiorrhizae (Danshen), bitter in flavor, slightly cold in property, has the therapeutic effectiveness of activating blood by resolving stasis, nourishing blood by tranquilizing mind, cooling blood by removing carbuncle and purging toxin 20 by promoting granulation. It has been regarded as a frequently-used blood activating and stasis-dissolving medicine. Not only does Danshen contain fat-soluble diterpenoids and water-soluble phenolic acids, but other components, e.g. flavonoids, triterpenes and sterols. Wherein, the diterpenoids with the structure of quinone and ketone include tanshinone I, tanshinone IIA, tanshinone IIR, tanshinone V, 25 tanshinone VI, cryptotanshinone, isotanshinone I, isotanshinone II, isotanshinone JIB and dihydrotanshinone I etc. The water-soluble phenolic acids include Danshensu, protocatechuic aldehyde, protocatechuic acid, caffeic acid and derivatives or depsides condensed with Danshensu and caffeic acid (e.g. , salvianolic acid A, salvianolic acid B, salvianolic acid C, salvianolic acid D, salvianolic acid E, salvianolic 30 acid G, Lithospermic acid B, rosmarinic acid and methyl rosmarinate etc.). Aforesaid 1 tanshinone IIA is one of the typical components in the blood-activating and stasis dissolving diterpenoids. As confirmed by modern pharmacological studies, Danshen has the functions of dilating coronary artery, anti-myocardial ischemia, anticoagulation, anti-formulation of thrombus, sedation, relieving pain, lowering 5 blood lipid and anti-atherosclerosis as well. In the present invention, hepatic fibrosis model induced with compound factor by CC1 4 was established and administrated by i.g. with high, medium and low dosage of the tested drugs of Radix Salviae Miltiorrhizae (RSM) preparations for 7 weeks. Bioactivities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), N 10 acetyl-p- D-glucosaminidase (NAG) and content of total protein (TP), albumin (ALB) and type IV collagen were measured in serum. Bioactivities of superoxide dismutase (SOD), malondialdehyde (MDA), Hyp were measured in liver. Pathomorphological change in liver was observed by HE and Masson staining. Expression of a-SMA was measured by immunohistochemistry. As shown in the result, RSM preparations do 15 have the effects of inhibiting the bioactivities of ALT, AST and NGA, lowering the content of type IV collagen in serum, increasing the content of TP and ALB in serum; decreasing the level of Hyp and MDA in liver tissue, increasing the bioactivity of SOD in liver tissue, restricting the growth of collagen fiber in liver tissue as well as reducing expression of a-SMA in liver tissue. 20 SUMMARY OF THE INVENTION The objective of the present invention is to provide a use of the RSM or its preparations in the manufacture of medicaments for treating hepatic fibrosis. Another objective of the present invention is to provide a use of RSM or its 25 preparations in the manufacture of medicaments for treating diseases related to hepatic fibrosis, e.g. liver cirrhosis, hepatitis or liver cancer, etc.. According to the present invention, said RSM may include the fresh RSM medicinal material, the processed RSM medicinal material or a product made from the RSM medicinal material. For example, the RSM is ground or extracted to give a product, in 30 which the extracting method include water-extracting method, ethanol-extracting 2 method or water-extracting and ethanol-precipitating method. Further, refining steps, e.g. resin purification, may be included. According to the present invention, said RSM preparations include the medicine which is made from the RSM medicinal material. By now, said RSM preparations 5 which are already commercially available include Salvia Tablets, Salvia Capsules and Salvia dripping pills. According to the present invention, said RSM preparations are prepared by a method comprising following steps: firstly the medicinal materials are processed to give bioactive components which are further made into the preparations. 10 According to the present invention, the preparing methods of the RSM preparations belong to the prior art, which can be obtained from the publication of Chinese patent or the published drug standard. According to the present invention, said RSM preparation is preferably selected from the RSM dripping pills. 15 According to the present invention, said RSM preparation is a pharmaceutical composition made from the RSM. Said composition comprises 0.1-99.9wt%of pharmaceutically acceptable carriers. Said pharmaceutical composition is prepared in the form of unit dosage and said unit dosage refers to individual preparation, e.g. each tablet of tablets, each capsule of capsules, each bottle of oral solutions, each bag 20 of granules and each injection of injections. According to the present invention, said RSM preparations can be prepared in any pharmaceutically acceptable dosage form, including the tablet such as sugar-coated tablet, film-coated tablet and enteric-coated tablet, the capsule such as soft capsule and hard capsule, the oral liquid solution, the buccal tablet, the granules, the instant 25 powder, the pill, the pulvis, the paste such as ointment and paster, the Dan, the suspension, the powder, the solution such as injection, the suppository, the cream, the spray, the drop, the dipping pill and the patch. According to the present invention, said orally-administrated dosage form can include commonly-used excipients such as the adhesive, filling agent, diluent, 30 tableting agent, lubricant, disintegrating agent, colorant agent, flavoring agent, 3 wetting agent. If necessary, the tablet may be coated. According to the present invention, suitable filling agents include cellulose, mannitol, lactose and other analogous filling agents. Suitable disintegrating agents include starch, polyvinylpyrrolidone (PVP) and starch derivative (i.g. sodium hydroxyethyl 5 starch). Suitable lubricants include magnesium stearate. Suitable wetting agents which are pharmaceutically acceptable include sodium dodecyl sulfate. According to the present invention, oral solid preparations of said composition can be prepared by commonly-used methods, e.g., blending, filling and tableting. By blending repeatedly, one can make the bio-active components (API) distributed 10 uniformly into a large amount of filling agent. According to the present invention, oral liquid preparations are in dosage form of either water-soluble or oil-soluble suspension, solution, emulsion, syrup or elixir, or drying powder that is always reconstituted with water or other suitable solvents before clinical use. This liquid preparation may contain conventional additives, for 15 example: suspending agent, e.g. sorbitol, syrup, methylcellulose, gelatin, hydroxy ethyl cellulose, hydroxy methyl cellulose, aluminum stearate gel or hydrogenated edible fat; emulsifying-agent, e.g. lecithin, sorbitan monoleate or arabic gum; non aqueous carriers (including edible oil) e.g. almond oil, fractionated coconut oil, oil ester (such as glyceride), propylene glycol or ethanol; as well as preservative e.g. 20 methylparaben, nipasol, sorbic acid. If necessary, conventional flavoring agents or colorant agents can be included. According to the present invention, said injection contains bio-active components and aseptic carriers. Said bio-active components can be dissolved or suspended depending on the type and concentration of carriers. Generally, a solution is 25 prepared by dissolving the bio-active component in the carrier, sterilizing, loading into a suitable vial or ampoule and sealing. Some adjuvants, e.g. local anaesthetic, preservative and buffering agent can be dissolved in the carrier. In order to improve its stability, after being loaded into the vial, this composition of the present invention can be froze and dried in vacuum to remove water. 30 According to the present invention, said RSM preparation can be prepared by 4 optionally adding pharmaceutically acceptable carriers. Said carriers include but are not limited to the substances selected from: sugar alcohol, e.g. mannitol, sorbitol, xylitol; amino acid, e.g. cysteine hydrochloride, methionine, glycine; Vitamin C; EDTA disodium, EDTA calcium disodium salt; inorganic salt, e.g. one valence alkali 5 carbonate, acetate, phosphate or its aqueous solution, sodium chloride, potassium chloride, sodium pyrosulfite, sodium bisulfite, sodium thiosulfate; calcium carbonate, calcium bicarbonate; stearate, e.g. calcium stearate, magnesium stearate; inorganic acid, e.g. hydrochloride, sulfate, phosphoric acid; organic acid, e.g. acetic acid, mercaptoacetic acid; organic acid salt, e.g. sodium lactate; oligosaccharide, 10 polysaccharide, cellulose and its derivatives, e.g. maltose, glucose, fructose, dextran, sucrose, lactose, cyclodextrin (p-cyclodextrin), starch; silicon derivative; alginate; gelatin; PVP; glycerol; Tween-80, agar gel; surfactant; polyethylene glycol (PEG); phospholipids; Kaolin; talcum powder etc. According to the present invention, protocol and dosage of said RSM preparation 15 depends on the condition of patients in clinic. For example, the RSM dripping pills prepared by the method of EXAMPLE 1 are administrated to patient, with 20 pills each time and 3 times daily, 24-32 weeks as a course of treatment. DESCRIPTION OF DRAWINGS 20 Fig.1 illustrates the influence of a-SMA expression by the RSM dripping pills in CCl 4 induced hepatic fibrosis in rats (10x20). Fig.2 illustrates the influence of pathologic morphology by the RSM dripping pills in CCl4-induced hepatic fibrosis in rats (HE straining, 10x10). Fig.3 illustrates the influence of pathologic morphology by the RSM dripping pills in 25 CCl4-induced hepatic fibrosis in rats (Masson straining, 10x10). EXAMPLES The following examples are offered for purposes of illustration only and do not intend to limit the scope of the invention in any way. 5 Example 1 preparation of the RSM dripping pill Formulation: Radix Salviae Miltiorrhizae 100g was used to give 1000 pills. 5 Preparing Method: Coarsely-ground Radix salvia Miltiorrhizae was placed into an extraction tank, into which water with 7 times the weight of the Radix salvia Miltiorrhizae crude medicine was poured to decoct for 2 times, 2 hours each time. After combination of the decoction, the solution was filtered and concentrated until the volume-to-weight 10 ratio was 1 L: 1kg to obtain an extract. The supernatant of the extract was collected by centrifugation and passed through the macroporous resin. The resin was washed with water, eluted with ethanol and the eluent was concentrated to give the RSM extract with the relative density of 1.31~1.38 (50-60'C) and concentration of no less than 10mg Danshensu in 1 gram of extract. Aforesaid RSM extract was added with a 15 proper amount of PEG, stirred well, melted on a water bath and transferred into the tank of dripping machine. Temperature was kept at 75~85'C. A Suitable dripper was selected in light of the weight of pill. Aforesaid RSM extract was dropped into the ice-bath cooled liquid paraffin with a speed of 60-80 pills per minute. After being formed, the pills were taken out and cleaned with blotting paper to remove the 20 surface liquid paraffin. The product was given. Example 2 preparation of RSM tablet Formulation: RSM extract 262g, starch 40g, light magnesium oxide 60g, magnesium stearate 7g, 25 talcum powder 80g to prepare 1000 tablets Preparing Method: Coarsely-ground Radix salvia Miltiorrhizae was extracted with 95% ethanol for 3 times, 2 hours each time. After ethanol recovery, the extract was concentrated to give a thick extract. Resulting drug residue was decocted with water for 2 times, 1 hour 6 for each time, and further filtered. The filtrate was concentrated to a proper volume and blended with aforesaid thick extract to have the RSM extract. Aforesaid RSM extract was heated (without direct flame) to 60'C-70'C, melted by stirring, added with the light magnesium oxide, talcum powder (60g) and starch 5 respectively, blended well and placed on a drying plate. The resulting materials were dried under 60'C to moisture content of no more than 3% and ground into granules (blocks) under mesh 14. Finally, the magnesium stearate and talcum powder (20g) were added, well blended to granulate with 12 mesh sieve, tableted, checked and coated with sugar. 10 Example 3 preparation of RSM capsule Formulation: RSM extract 406g, starch 40g, and 10% starch slurry to prepare 1000 capsules Preparing Method: 15 Coarsely-ground Radix salvia Miltiorrhizae was extracted with 95% ethanol for 3 times, 2 hours each time. After ethanol recovery, the extract was concentrated to give a thick extract. Resulting drug residue was decocted with water for 2 times, 1 hour for each time, and further filtered. The filtrate was concentrated to a proper volume and blended with aforesaid thick extract to have the RSM extract. 20 Aforesaid RSM extract was pulverized and passed 80 mesh sieve and added with 10% starch slurry to make soft material to granulate by 14 mesh nylon sieve. The resulting granules were dried at 70'C to the moisture content of no more than 3%. These granules were blended and loaded into #1 capsule shell to give the product. 25 Example 4 preparation of RSM granule Formulation: RSM 100g to prepare 1000 granules Preparing Method: 7 Coarsely-ground Radix salvia Miltiorrhizae was placed into an extraction tank, into which water with 7 times the weight of the Radix salvia Miltiorrhizae crude medicine was poured to decoct for 2 times, 2 hours each time. After combination of the decoction, the solution was filtered and concentrated until the volume-to-weight 5 ratio was 1 L: 1kg to obtain an extract. The supernatant of the extract was collected by centrifugation and passed through the macroporous resin. The resin was washed with water, eluted with ethanol and the eluent was concentrated to give the RSM extract with the relative density of 1.31~1.38 (50-60'C) and concentration of no less than 10mg Danshensu in 1 gram of extract. Aforesaid RSM extract was added with 5 10 times of sugar powder, blended well, added with 70% ethanol to make a soft material. Aforesaid soft material was granulated by 14 mesh nylon sieve. The resulting wet granules were dried at 60'C. The dried granules were sieved firstly by 14 mesh sieve and by No. 4 sieve (65 mesh) to get rid of the fine powder, loaded separately, sealed to give the product. 15 Trial example 5: Efficacy study of RSM preparations Activation of the HSC (hepatic stellate cell) and extracellular matrix (ECM) overdeposition are both believed to be the crucial events to hepatic fibrosis. Always, the activated HSC is proliferated, and converted into myofibroblast to generate a 20 large amount of ECM. CCl4-induced hepatic fibrosis was used in this experiment, because its mechanism lies in that it can directly hydrolyze membrane of liver cell, leading to liver cell degenerative necrosis. Toxicity of CCl4 is mainly related to its active metabolite. CCl 4 is metabolized into active chloroform free radicals and chloride radicals by mixed function oxidase in liver cells. These free radicals can 25 finally make enzyme of the liver cell lose function, membrane lipid peroxidation and concentration of calcium increased, causing liver cell injured necrosis and fibrosis. This fibrosis model, however, has self-cure tendency. So the research was carried out in a manner of preventive administration. Activities of ALT and AST are sensitive biomarker for injury of liver cells. Reduction of TP and ALB is in proportion to the 30 injury of synthetic function in liver cell. One of the key factors of hepatic fibrosis is ECM overdeposition. Collagen is the main 8 constituent of ECM and Hyp is the main constituent of collagen. Hyp of liver cell, changing with the decrease/increase of collagen during the progress of fibrosis, is identified as the important marker for evaluation of collagen content and degree of liver fibrosis. NAG, a proteolytic enzyme of lysosome, takes part in hydrolytic 5 metabolism of connective tissue matrix. Its activity in serum is thought to be correlated with the hepatic fibrosis, revealing connective-tissue-collagen decomposition. Similarly, the change of content of type IV collagen in serum is confirmed to be an extremely practical marker to judge degree of hepatic fibrosis. Under normal conditions, HSC remains in stationary state. Under pathological 10 conditions, HSC is activated, and expresses a-SMA (a-smooth muscle actin). The SMA expressed by HSC is seen as one of its significant characteristics. Immunohistochemical technique and image analysis software were used to analyze a-SMA to show the effect of medicine. On the basis of aforesaid factors, a pharmacological experiment for the RSM 15 preparations had been designed as follows: 1. Material 1.1 Animals Wistar male rats, weighing 140-160g, were purchased from Tianjin Shanchuanhong 20 Animal Co., Ltd. (Certification number: SCXK (JIN) 2009-0001). 1.2 Reagents ALT, AST, TP and ALB kits were obtained from BioSino Bio-technology and Science Inc. SOD, MDA, Hyp and NGA kits were purchased from Nanjing Jiancheng 25 Biochemical Institute. Type IV collagen kit was purchased from Adlitteram diagnostic laboratories Inc. a-SMA mouse monoclonal antibodies were obtained from abcam Inc. Monoclonal antibody kit, DAB coloring kit were purchased from Beijing Zhongshanjinqiao Inc. CCI was purchased from Tianjin Tianhe Reagent Factory. Fuzhenghuayu (FZHY) capsule (Batch No.: 100403) was purchased from 30 Shanghai Huanghai Pharmaceutical Company, and resolved with distilled water to 9 prepare suspension before use. The RSM dripping pill (Batch No.: 100101) was produced by Tianjin Tasly Pharmaceutical Co., Ltd in accordance with the method of EXAMPLE 1. 5 1.3 Apparatus LXJ-IIB low-speed large-capacity multi-tube centrifuge was purchased from Shanghai Anting Apparatus Inc. SUNRISE enzyme mark instrument was produced by SUNRISE Austria. PL 203 electronic balance was produced by METTLER TOLEDO (Shanghai) Inc. Hitachi 7080 auto chemistry analyzer was produced by 10 Hitachi Inc Japan. Olympus BH-2 ordinary microscope was purchased from Olympus Inc Japan. 2. Method 2.1 Establishment of model 15 Except the control group, the rats in other groups were injected subcutaneously (sc) with pure CCl 4 at 5ml/kg for the first time and then with 400% sc pure CCl4-olive oil at 3ml/kg every 3 days for 7 weeks. During first 2 weeks, the rats were fed with diet of 20% pig oil and 0.5% cholesterol and simple corn meat diet during 3rd to 6th week. 20 2.2 Grouping and administration 90 healthy male rats, weighing 140g~160g, were randomly divided into 6 groups: control group (n=10), model group (n=16), FZHY group (1500mg/kg, n=16), RSM dripping pill high-dose (700mg/kg), medium-dosage (350mg/kg) and low-dosage (175mg/kg) groups (n=16). The rats were administrated with corresponding 25 medicines by i.g. at the day of making model and with distilled water (10mL/kg) to the control and model group for 7 weeks. 1 hour after last administration, the rats were anesthetized by intramuscular injection of pentobarbital sodium to draw blood from abdominal aorta. Serum was collected by centrifuge for later use. Hepatic tissue at same position was quickly taken out, fixed in 12% formalin liquid for HE staining 10 and Masson staining. Hepatic tissue in other position was fixed in 10% formalin liquid for immunohistochemical staining and the rest of hepatic tissue was prepared into 10% liver tissue homogenate by normal saline. 5 2.3 Measurement of biomarker Biomarkers were measured, e.g. activity of ALT, AST, content of TP, ALB, NAG and type IV collagen, activity of hepatic SOD and content of MDA and Hyp, expression of a-SMA by immunohistochemical staining, HE staining and Masson Staining after paraffin section. 10 2.4 Expression of a-SMA in hepatic tissue measured by immunohistochemical method The paraffin sections were deparaffinized by normal method, hydrated and washed with PBS for 15min. Intrinsic peroxidase was closed with 3% H 2 0 2 , incubated at 15 room temperature for 10min and washed with PBS for 15min. Further, they were placed 0.01mol/L sodiocitrate buffering solution to repair for 15min on electrical magnetism stove, washed for 15min with PBS after self cooling and unnecessary solution was removed. ci-SMA monoclonal antibody (1:100) was dripped, incubated at 37'C for 1 hour and washed with PBS for 15min. Polymer Helper was dripped, 20 incubated at 37'C for 20 min, and washed with PBS for 15 min. Poly-HRP anti-Mouse IgG monoclonal antibody was dripped, incubated at 37'C for 20 min, washed with PBS for 15min, colored by DAB, washed with tap water for 10min, re-stained by hematoxylin, dehydrated, cleared and sealed for microscopic examination. The a SMA staining was brownish yellow. The image was analyzed with image analysis 25 software (Image-Proplus 6.0) and 5 fields of vision were selected randomly to record integral optical density (IOD). The more IOD value is, the stronger positive expressive products are. 2.5 Histopathological examination 30 After HE staining and Masson staining, the degree of liver fibrosis was examined 11 under microscope and analyzed semi-quantitatively. Grading standards of hepatic fibrosis were present as follows: "-_" represented normal liver, in which extremely few fibrous connective tissue was observed in portal area, which is in a normal state; 5 "+"represented collagen proliferation in portal area and around central vein in hepatic lobule, where few fibrosis bundle spread and irradiation in central vein and portal vein was observed without formation of fibrous septa and hepatic lobules remained unchanged; " + + " represented collagen proliferation, where fibrosis bundle spread and 10 irradiation in central vein and portal vein was observed with formation of incomplete interval, and hepatic lobules reserved mostly; "++++ " represented mass collagen proliferation, where small amount of false lobe was formed with destruction of the lobular structure; ++++ + " represented thickened septal and false lobe was formed. 15 2.6 Statistical analysis SPSS11.5 software package was used to analyze data and t-test was used to analyze the inter-group difference. Data were expressed as 3 ± s. Lesion degree of pathological tissues was analyzed with SPSS11.5 NPar Tests Mann-Whitney Test and 20 illustrated by Excel. 3. Results 3.1 Effect on serum ALS, AST, TP and ALB of hepatic fibrosis rats As shown in Table 1, compared with the control group, the activity of serum ALT 25 and AST was increased significantly (P<0.01) and the content of TP and ALB reduced significantly (P<0.01). Compared with the model group, the content of TP and ALB in the RSM dripping pill groups of medium and low dosage was increased significantly (P<0.05) and the activity of serum ALT and AST reduced significantly (P<0.05). 12 3.2 Effect on serum NGA and type IV collagen of hepatic fibrosis rats As shown in Table 2, compared with the control group, the activity of serum NGA was increased significantly (P<0.01) and type IV collagen increased. Compared with 5 the model group, activity of serum NGA in the RSM dripping pill groups of 3 dosages was reduced significantly (P<0.01) and content of type IV collagen in the RSM dripping pill medium-dosage and low-dosage groups was reduced (P<0.05). 3.3 Effect on activity of SOD and level of MDA and Hyp in liver tissue of hepatic 10 fibrosis rats As shown in Table 3, compared with the control group, activity of SOD in liver tissue of model rats was reduced significantly (P<0.05), and level of MDA and Hyp was increased significantly (P<0.01). Compared with the model group, activity of SOD in the RSM dripping pill groups of 3 dosages was increased significantly (P<0.05), the 15 level of MDA in the RSM dripping pill low-dosage group reduced significantly (P<0.05) and level of Hyp in the RSM dripping pill groups of 3 dosages reduced significantly (P<0.01). 3.4 Effect on expression of a-SMA in liver tissue of hepatic fibrosis rats 20 As shown in Fig.1 and Table 4, positive staining in the control group was found in vessel wall. Compared with the control group, the positive expression of a-SMA in the model group was strengthened clearly. Positive staining was widely expressed in the fibrous septa, vessel wall and fibrous tissue proliferation area. There was no expression in biliary tract cell. Distribution of a-SMA positive expression in the RSM 25 dripping pill groups of 3 dosages was similar with the ones in the model group, but yellow sclera area was somewhat reduced. By IOD examination, compared with the control group, the IOD value in was increased significantly (P<0.05). Compared with the model group, the IOD values in the RSM dripping pill groups of medium and low dosages were reduced significantly (P<0.05). As shown in the results, the RSM 30 dripping pills can resist the enhancement of the a-SMA expression and inhibit HSC 13 proliferation in liver tissue of hepatic fibrosis rats. 3.5 Effect on pathologic morphology in liver tissue of hepatic fibrosis rats As shown in Table 5, Fig. 2 and Fig. 3, it was found that the hepatic lobule in control 5 group was integral, tissue was clear, liver cells were morphologically normally arranged in cords centered by central vein and liver sinus was clear. There were extremely few fibrosis tissues in a bigger portal area, which is in a normal state. Compared with the control group, hepatic lobules in rats of the model group were damaged at different levels, hepatic cells arranged in disorder, fibrosis tissues 10 proliferated at different levels in portal area, central vein and portal vein, indicating successful modeling. Aforesaid diseases were found in rats of administration groups, significantly less than that of the model group. Fibrosis of rats was graded in light of pathological change and grading standard of fibrosis at home and abroad. Significance test was for grading result. The RSM dripping pills of 3 dosages can 15 improve the hepatic fibrosis markedly (P<0.05, P<0.01). As shown in the results, the RSM has significantly protective effect on hepatic fibrosis rats. Table 1 Effect of RSM dripping pills on serum ALS, AST, TP and ALB in CCl 4 induced hepatic fibrosis rats ( x ±s) Groups n dosage ALT AST ALB TP (mg.kg-') (U.-') (U.L-') (g.L') (g.L') Control 10 - 35.49±6.99 160.90±21.85 33.4±1.0 59.06±2.59 group Model 9 - 98.17±55.38"" 232.99±96.09 27.74±3.76"" 47.93±4.75"" group FZHY 10 1500 34.35±3.51** 152.62±12.02* 29.91±1.12 50.66±2.14 capsule RSM 9 700 69.06±25.62 179.38±25.06 30.11±2.13 51.86±3.39 RSM 10 350 40.85±12.49* 154.50±23.21* 31.33±1.45* 53.68±3.37* RSM 9 175 46.74±11.75* 170.19±26.27 31.44±1.14* 52.79±1.72* 20 Compared with the control group, ^^P <0.01; compared with the model group, *P<0.05, **P<0.01 14 Table 2 Effect on serum NGA and type IV collagen in CCl4-induced hepatic fibrosis rats ( x ±s) Groups N Dosage NAG(U. L 1 ) Type IV collagen (mg- kg-1) (ng-mfl-1) Control 10 - 24.87±8.20 0.64±0.16 group Model 9 - 38.45±7.53"" 1.04±0.70 group FZHY 10 1500 21.27±10.15** 0.55±0.23 capsule RSM 9 700 28.32±6.56** 0.89±0.47 RSM 10 350 25.90±8.78** 0.49±0.19* RSM 9 175 28.23±5.47** 0.46±0.06* Compared with the control group, 'P<0.01; compared with the model group, *P<0.05, **P<0.01 5 Table 3 Effect on activity of SOD and level of MDA and Hyp in liver tissue of CCl4-induced hepatic fibrosis rats ( x ±s) Groups n Dosage SOD MDA Hyp (mg.kg 1 ) (U.ml- 1 ) (nmol.mgprot-') ( g (g of liver)- 1 ) Control 10 - 63.01±14.22 1.21±0.29 127.89±13.68 groups Model 9 - 46.06±13.313' 5.18±2.70'4 242.11±56.134 groups FZHY 10 1500 54.77±8.28 4.12±2.27 165.26±38.81** capsule RSM 9 700 58.01±9.34* 3.73±1.49 177.58±56.82* RSM 10 350 58.41±11.12* 3.87±2.47* 176.49±34.89* RSM 9 175 58.46±5.70* 2.22±0.51 157.12±31.11* Compared with the control group, 4P<0.05, "4P<0.01; compared with the model group, *P<0.05, **P<0.01 10 15 Table 4 Effect on expression of a-SMA in liver tissue of CCl4-induced hepatic fibrosis rats ( x ±s) Groups n Dosage (mg.kg ') IOD(x10 2 ) Control groups 10 - 5.08±0.81 Model groups 9 - 20.54±6.71" FZHY capsule 10 1500 9.62±3.53* RSM 9 700 12.12±2.92 RSM 10 350 9.75±1.68* RSM 9 175 8.39±1.25* Compared with the control group, 4P<0.05; compared with model group, *P<0.05,**P<0.01 5 Table 5 Effect on pathologic morphology in liver tissue of CC14-induced hepatic fibrosis rats Degree of hepatic fibrosis Groups n - + ++ +++ ++++ P value Control group 10 10 0 0 0 0 .0000 Model group 9 0 0 1 7 1 FZHY capsule 10 0 3 3 3 1 0.056 RSM high dosage 9 0 2 4 2 1 0.045 group RSM medium dosage 10 0 2 5 2 1 0.028 group RSM low dosage 9 0 4 5 0 0 0.000 group Compared with the model group, *P<0.05, **P<0.01 As shown in the results, the RSM dripping pills can significantly inhibit the increase 10 of ALT and AST and enhance synthesis of TP and ALB, especially for the medium and low dosages. It is shown that the RSM dripping pills have the effect of protecting liver cell and inhibiting liver damage. As shown in the results, the RSM dripping pills can inhibit the increase of Hyp and type IV collagen and reduce the activity of NAG, especially for the medium and low 16 dosages. It is shown that the RSM dripping pills have the effect of inhibiting precipitation of collagen by promoting degradation of collagen, significantly improving the degree of hepatic fibrosis. Change of SOD and MDA displays the degree of liver damage directly or indirectly. As shown in the results, the RSM 5 dripping pills can increase the activity of SOD, lowering the level of MDA, especially for the medium and low dosages. It is indicated that the RSM dripping pills have the effect of lowering free radical and reducing lipid peroxidation. As shown in the results, the RSM dripping pills can inhibit higher expression of a SMA, especially for medium and low dosages. It is shown that the RSM dripping 10 pills have effect of inhibiting HSC proliferation. Its mechanism of anti-fibrosis has the relationship with inhibiting expression of a-SMA by HSC. As shown in the results of pathological examination, the RSM dripping pills can significantly improve damage caused by hepatic fibrosis, especially for the and low dosages, indicating the protective effect on hepatic fibrosis rats. 15 REFERENCE [1] Adrian JE, Poelstra K, Scherphof GL, et al. Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct-ligated rats [J]. J Pharmacol Exp Ther, 2007, 321(2):536-543. 20 [2] Prud home GJ. Pathobiology of transforming growth factor beta in cancerfibrosis and immunologic disease, and therapeutic consideration [J]. Lab Invest, 2007, 87(11):1077-1091. [3] Song M, Song Z, Barve S, et al. Tetrathiomolybdate protects against bile duct ligation-induced cholestatic liver injury and fibrosis [J]. J Pharmacol Exp Ther, 2008, 25 325(2):409-416. [4] Miao XD, Yan J, Ying BZ, et al. Emodin protects rat liver from CCL4-induced fibrogenesis via inhibition of hepatic stellate cells activation [J]. World J Gastroenterol, 2009, 15(38):4753-4762. [5] ZOU YH, Yang Y, Li J, Wu Q, et al. Potential therapeutic effects of a traditional 30 Chinese formulation, BJ-JN, on liver fibrosis induced by carbon tetrachloride in rats 17 [J]. J Ethnopharmacol, 2008, 120(3):452-457. [6] Yuan LP, Chen FH, Ling L, et al. Protective effects of total flavonoids of Bidens bipinnata L. against carbon tetrachloride-induced liver fibrosis in rats [JI. J Pharm Pharmacol, 2008, 60(10):1393-1402. 5 [7] Qin Y, Yan L, Tang L, et al. Effect of tanshinone IIA on collagen expression in liver tissue of hepatic fibrosis ras [J]. Lishizhen Medicine and Materia Medica Research, 2010, 21(4): 782-784. [8] Chen H, Zhang JH, Liu WQ, Effect of curcumin for anti-schistosomiasis hepatic fibrosis and the experimental study of its mechanism [J]. Chinese Traditional and 10 Herbal Drugs, 2010, 40(8): 1274-1277. [9] Xu SY, Bian RL, Chen X, Experimental Methodology of Pharmacology [MI. 3rd Edition, People's Medical Publishing House, Beijing, 2005. [10] Cai WM, Zhang BB, Weng HL et al., Comparison study of eight markers of hepatic fibrosis serum [J]. Chinese Journal of Hepatology, 2004, 12(4): 219. 15 [11] Chen LY, Dynamic effect of ShuGanRuanJian Decoction on NAG of hepatic fibrosis rats [J]. Journal of Shanxi College of Traditional Chinese Medicine, 2003, 4(3): 13-14. [12] Wang GS, Han ZW, Effect of glycyrrhiza flavonoids on liver damage caused by ethanol [JI. Acta Pharmacologica Sinica, 1993, 9(4): 271-274. 20 [13] Zhou CY, Ai LY, Wang M, et al., Experimental study of Eucommia polysaccharide for anti hepatic fibrosis [J]. Chinese Traditional and Herbal Drugs, 2011, 42(2): 324-329. 18
    权利要求:
    Claims (10)
    [1] 1. A use of Radix Salviae Miltiorrhizae or its preparations in manufacture of medicaments for anti hepatic fibrosis diseases. 5
    [2] 2. The use according to claim 1, characterized in that said use includes the use for treating diseases related to hepatic fibrosis
    [3] 3. The use according to claim 2, characterized in that said use includes the use for 10 treating liver cirrhosis, hepatitis, liver cancer.
    [4] 4. The use according to claim 1, characterized in that said use includes use for inhibiting activity of ALT, AST and NGA. 15
    [5] 5. The use according to claim 1, characterized in that said use includes use for reducing level of type IV collagen, increasing level of TP and ALB in serum and reducing level of Hyp and MDA in liver tissue.
    [6] 6. The use according to claim 1, characterized in that said use includes use for 20 increasing activity of SOD and inhibiting increase of collagen fiber in liver tissue.
    [7] 7. The use according to claim 1, characterized in that said use includes use for reducing a-SMA expression in liver tissue. 25
    [8] 8. The use according to claim 1, characterized in that said Radix Salviae Miltiorrhizae preparations are the medicines prepared by using Radix Salviae Miltiorrhizae as crude medicine.
    [9] 9. The use according to claim 8, characterized in that said Radix Salviae Miltiorrhizae 30 preparations include Radix Salviae Miltiorrhizae tablets, Radix Salviae Miltiorrhizae capsules, Radix Salviae Miltiorrhizae dripping pills. 19
    [10] 10. The use according to claims 9, characterized in that said said Radix Salviae Miltiorrhizae preparation include Radix Salviae Miltiorrhizae dripping pills. 20
    类似技术:
    公开号 | 公开日 | 专利标题
    US7438935B2|2008-10-21|Pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases
    US9987320B2|2018-06-05|Traditional chinese medicine composition, and preparation and application thereof
    EP3020408B1|2022-01-12|Traditional chinese medicine composition, and preparation and application thereof
    CN104415045B|2019-03-22|A kind of pharmaceutical composition
    CA2932187C|2021-06-22|New salvianolic acid compound t, preparation method therefor, and use thereof
    US20070160626A1|2007-07-12|Medicinal composition for liver diseases
    RU2700793C2|2019-09-23|Pharmaceutical composition containing silybin, vitamin e and l-carnitine
    Sun et al.2007|Effects and mechanisms of extract from Paeonia lactiflora and Astragalus membranaceus on liver fibrosis induced by carbon tetrachloride in rats
    TW201309208A|2013-03-01|Food formulation for nutrition-caring multiple types of stem cells and preparation method thereof
    CN106176837B|2020-02-21|Pharmaceutical composition, preparation method and application thereof
    Ai et al.2019|Amelioration of dry eye syndrome in db/db mice with diabetes mellitus by treatment with Tibetan Medicine Formula Jikan Mingmu Drops
    Mukhtar et al.2021|Hepatoprotective activity of silymarin encapsulation against hepatic damage in albino rats
    CN100512830C|2009-07-15|Pharmaceutical composition for treating senile dementia
    AU2013207295B2|2017-10-19|Use of radix salviae miltiorrhizae | or its preparations in preparation of drugs for treating diseases related to hepatic fibrosis
    WO2008145064A1|2008-12-04|The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof
    Liu et al.2021|Polyphenols from blue honeysuckle | berry inhibit lipid accumulation in adipocytes by suppressing lipogenesis
    KR20140138275A|2014-12-03|Herbal compositions for the treatment of metabolic disorders
    JP2021512062A|2021-05-13|Composition containing berberine
    CN110251524A|2019-09-20|The preparation method of compound lobetyolin | and the new application in drug and health care product
    Ma et al.2020|Aqueous extraction from dachengqi formula granules reduces the severity of mouse acute pancreatitis via inhibition of pancreatic pro-inflammatory signalling pathways
    Li et al.2021|Codonopis bulleynana Forest ex Diels | effectively attenuates hepatic fibrosis in CCl4-induced fibrotic mice model
    Wu et al.2020|Study on the potential effective ingredients of Xiaosheng prescription for dry eye disease
    CN106511460B|2020-10-02|Chinese medicinal composition for treating hepatic fibrosis
    Li et al.2021|A Review on the Phytochemical and Pharmacological Properties of Rosa laevigata: A Medicinal and Edible Plant
    CN112717031A|2021-04-30|Pharmaceutical composition for treating Alzheimer&#39;s disease and preparation method thereof
    同族专利:
    公开号 | 公开日
    RU2623147C2|2017-06-22|
    CA2862442A1|2013-07-11|
    US20150044310A1|2015-02-12|
    JP2015503572A|2015-02-02|
    AU2013207295B2|2017-10-19|
    EP2801365A4|2016-03-02|
    US9895405B2|2018-02-20|
    RU2014130412A|2016-02-20|
    KR20140114398A|2014-09-26|
    WO2013102437A1|2013-07-11|
    EP2801365A1|2014-11-12|
    CN103191186A|2013-07-10|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    CN1060655C|1995-08-04|2001-01-17|刘三都|Medicine for hepatitis|
    CN1083721C|1999-03-29|2002-05-01|首都医科大学附属北京友谊医院|Compound Chinese herb medicine for curing fibrosis of liver and hepatocirrhosis and its preparation method|
    CN1163227C|1999-04-19|2004-08-25|上海中医药大学|Application of tanhin polyphenolic B magnesium in preparing medicine for treating chronic hepatosis|
    US8486464B2|2000-12-22|2013-07-16|Tasly Pharmaceutical Group Co. Ltd.|Herbal composition for angina pectoris, method to prepare same and uses thereof|
    CN1283258C|2003-03-11|2006-11-08|北京金桥时代生物医药研究发展中心|Medicine for preventing fibrous liver and preparing method thereof|
    CN1274711C|2004-04-02|2006-09-13|江苏正大天晴药业股份有限公司|Method of preparing general phenolic acid of red sange root for treating hepatic fibrosis|
    ITRM20040439A1|2004-09-16|2004-12-16|Ca Di Group S R L|PRODUCT WITH SELECTIVE ANTI-INFLAMMATORY ACTION AND ACTION AGAINST TISSUE FIBROGENESIS.|
    CN100411642C|2004-10-15|2008-08-20|合肥恒星药物研究所|Medication for treating chronic hepatitis|
    CN1839819A|2005-01-28|2006-10-04|海口绿科南药研究开发有限公司|Medicinal composition containing tanshinone and its preparation process and usage|
    KR100725839B1|2005-10-06|2007-12-11|일성신약주식회사|Composition comprising tanshinone compounds isolated from the extract of salviae miltiorrhizae radix for treating or preventing cognitive dysfunction|
    CN100571720C|2006-01-05|2009-12-23|北京华医神农医药科技有限公司|A kind of medicine for the treatment of hepatic fibrosis and preparation method thereof|
    CN101596202A|2008-06-04|2009-12-09|四川思达康药业有限公司|The application of tanshinone IIA emulsion in the treatment hepatopathy|
    CN102160872A|2010-02-23|2011-08-24|天津天士力制药股份有限公司|Compound salvia dropping pill capsules|CN108949677B|2018-07-05|2021-11-30|浙江大学|Application of rehmannia root glycoside C and salvianolic acid A in promoting proliferation of mesenchymal stem cells cultured in vitro and inhibiting replicative senescence|
    法律状态:
    2018-02-15| FGA| Letters patent sealed or granted (standard patent)|
    2020-07-30| MK14| Patent ceased section 143(a) (annual fees not paid) or expired|
    优先权:
    申请号 | 申请日 | 专利标题
    CN201210000557.6||2012-01-04||
    CN2012100005576A|CN103191186A|2012-01-04|2012-01-04|Application of salvia miltiorrhiza preparation in preparing anti-liver-fibrosis medicines|
    PCT/CN2013/070037|WO2013102437A1|2012-01-04|2013-01-04|Uses of danshen or danshen preparation in preparation of drugs for treating diseases related to hepatic fibrosis|
    [返回顶部]